Abstract:Background: Synthetic lethality (SL) refers to the genetic interaction between two or more genes where only their co-alteration (e.g. by mutations, amplifications or deletions) results in cell death. In recent years, SL has emerged as an attractive therapeutic strategy against cancer: by targeting the SL partners of altered genes in cancer cells, these cells can be selectively killed while sparing the normal cells. Consequently, a number of studies have attempted prediction of SL interactions in human, a majority by extrapolating SL interactions inferred through large-scale screens in model organisms. However, these predicted SL interactions either do not hold in human cells or do not include genes that are (frequently) altered in human cancers, and are therefore not attractive in the context of cancer therapy. Results: Here, we develop a computational approach to infer SL interactions directly from frequently altered genes in human cancers. It is based on the observation that pairs of genes that are altered in a (significantly) mutually exclusive manner in cancers are likely to constitute lethal combinations. Using genomic copy-number and gene-expression data from four cancers, breast, prostate, ovarian and uterine (total 3980 samples) from The Cancer Genome Atlas, we identify 718 genes that are frequently amplified or upregulated, and are likely to be synthetic lethal with six key DNA-damage response (DDR) genes in these cancers. By comparing with published data on gene essentiality (~16000 genes) from ten DDR-deficient cancer cell lines, we show that our identified genes are enriched among the top quartile of essential genes in these cell lines, implying that our inferred genes are highly likely to be (synthetic) lethal upon knockdown in these cell lines.

Synthetic Lethality in Drug Development: the Dawn is Coming

Synthetic Lethality: a Promising Therapeutic Strategy for Hepatocellular Carcinoma.

Synthetic lethal strategies for the development of cancer therapeutics

The power and the promise of synthetic lethality for clinical application in cancer treatment

Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation

Synthetic lethality as an engine for cancer drug target discovery

Synthetic Lethal Interactions in Cancer Therapy

Complex synthetic lethality in cancer

Exploiting synthetic lethal vulnerabilities for cancer therapy

An update on small molecule compounds targeting synthetic lethality for cancer therapy

Potential promising of synthetic lethality in cancer research and treatment

Cyclin-dependent kinases-based synthetic lethality: Evidence, concept, and strategy

The tumor therapy landscape of synthetic lethality

SL-BioDP: Multi-Cancer Interactive Tool for Prediction of Synthetic Lethality and Response to Cancer Treatment

Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand

Synthetic Lethality in Ovarian Cancer

Computational methods, databases and tools for synthetic lethality prediction

Inferring synthetic lethal interactions from mutual exclusivity of genetic events in cancer

PARP-inhibitor-induced synthetic lethality for acute myeloid leukemia treatment

Breast Cancer Predisposition Genes and Synthetic Lethality

PARP inhibitors: Synthetic lethality in the clinic